Cite

    Hu, Y., Zhang, H., Li, X., Mai, J., Yang, L., Yan, J., Li, Y., Sun, J., Xu, W., He, S., Li, J., & Wu, M. (2022). a randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers. Expert opinion on investigational drugs, 31, 977–985. http://access.bl.uk/ark:/81055/vdc_100167016089.0x000030